What do you do when a loved one becomes chronically ill?

Third Age blog post, by Suzan Jackson: What do you do when a loved one becomes chronically ill?

Sooner or later, it happens to all of us. A beloved friend or family member develops a chronic illness, and their life changes dramatically with that diagnosis and new restrictions. Of course, we want to be there for our loved one – to say just the right thing and offer help – but the sad truth is that many people instead say nothing, for fear of saying the wrong thing.

Here’s how Suzan Jackman suggests you reach out to your friend or family member to support them when they need you most, based on the experiences of people who are chronically ill:

Don’t Say Nothing

Do Try Simple Statements of Support

Don’t Offer To Help Without Specifics

Do Help in Specific Ways

Don’t Offer Unsolicited Advice

Do Pass Along Scientific Studies (But Not Too Often)

Don’t Make Unplanned Visits or Phone Calls

Do Show Your Support

Don’t Pretend Everything Is Fine

Do Acknowledge the Illness & Show Interest

Don’t Pity or Judge Your Loved One

Do Show Compassion, Empathy, and Acceptance

Don’t Take Cancellations or Absences Personally

Do Keep Inviting!

Read the full article

Read more by Suzan Jackson  and Live with CFS

 

Posted in News | Tagged , | Comments Off on What do you do when a loved one becomes chronically ill?

Tuller says FITNET fraught with misrepresentations & methodological problems

Virology blog post, by David Tuller, 21 November 2016: Trial By Error, Continued: The New FITNET Trial for Kids

The article challenges:

  • the failure of PACE researchers to acknowledge failings of PACE
  • the unproven use of CBT to reverse false illness beliefs and deconditioning
  • Crawley’s FITNET study
  • Crawley’s earlier study that concluded CFS affects 1.9% of 16 year olds
  • Dutch FITNET study
  • CFS research & discussion in Netherlands

Tuller on FITNET:

Like the work of the PACE authors, Dr. Crawley’s research is fraught with misrepresentations and methodological problems. Like them, she routinely conflates the common symptom of chronic fatigue with the illness called chronic fatigue syndrome—a serious error with potentially harmful consequences. (I will mostly use chronic fatigue syndrome in describing the research because that is the term they use.)

Dr. Crawley favors subjective over objective outcomes. In PACE, of course, the objective measures–like a walking test, a step-test for fitness, and employment status—all failed to demonstrate “recovery” or reflect the reported improvements in the two primary subjective outcomes of physical function and fatigue. FITNET-NHS doesn’t even bother with such measures. The primary outcome is a self-report questionnaire assessing physical function, and almost all the secondary outcomes are also subjective.

This is particularly troubling because FITNET-NHS, like PACE, is non-blinded; that is, both participants and investigators know which intervention they are receiving. Non-blinded studies with subjective outcomes are notoriously vulnerable to bias—even more when the intervention itself involves telling participants that the treatment will make them better, as is the case with the kind of cognitive behavior therapy provided for ME/CFS patients.

The FITNET-NHS study protocol states that participants will be identified using the guidelines developed by NICE—the U.K.’s National Institute for Health and Care Excellence. The protocol describes the NICE guidelines as requiring three months of fatigue, plus one or more of nine additional symptoms: post-exertional malaise, difficulty sleeping, cognitive dysfunction, muscle and/or joint pain, headaches, painful lymph nodes, general malaise, dizziness and/or nausea, or palpitations. In other words, according to the protocol, post-exertional malaise is not required to participate in FITNET-NHS; it is clearly identified as an optional symptom. (In the U.K., the illness can be diagnosed at three months in children, rather than at six months.)

But the proposal’s claim to be following the NICE guidelines does not appear to be true. In the NICE guidelines, post-exertional malaise is not an optional symptom. It is required, as an essential element of the fatigue itself. (In addition, one or more of ten other symptoms must also be present.) To repeat: post-exertional malaise is required in the NICE guidelines, but is not required in the description of the NICE guidelines provided in the FITNET-NHS protocol.

By making this subtle but significant shift—a sleight-of-guideline, so to speak—Dr. Crawley and her colleagues have quietly transformed their prospective cohort from one in which post-exertional malaise is a cardinal characteristic of the illness to one in which it might or might not be present. And they have done this while still claiming–inaccurately–to follow NICE guidelines. As currently described, however, Dr. Crawley’s new study is NOT a study of chronic fatigue syndrome, as she maintains, but of chronic fatigue.

As a result, the actual study participants, like the PACE cohort, will likely be a heterogeneous grab bag of kids suffering from fatigue for any number of reasons, including depression–a common cause of exhaustion and a condition that often responds to psychotherapeutic interventions like CBT. Some or even many participants—an unknown number—will likely be genuine ME/CFS patients. Yet the results will be applied to ALL adolescents identified as having that illness. Since those who actually have it suffer from the required symptom of post-exertional malaise, an intervention that encourages them to increase their activity levels, like CBT, could potentially cause harm.

(I suppose it’s possible the FITNET-NHS protocol’s inaccurate description of the role of post-exertional malaise in the NICE guidelines was inadvertent, a case of sloppiness. If so, it would be an extraordinary oversight, given the number of people involved in the study and the enormous implications of the switch. It is curious that this obvious and jarring discrepancy between the NICE guidelines and the FITNESS-NHS description of them was not flagged during the review process, since it is easy to check whether the protocol language accurately reflects the recommendations.)

Dutch FITNET study:

The approach to CBT in the Dutch FITNET trial reflects that in the U.K. Of the online intervention’s 21 modules, according to the protocol for the Dutch study, fourteen “focus on cognitive behavioural strategies and include instructions and exercises on how to identify, challenge and change cognitive processes that contribute to CFS.” Of course, experts outside the CBT/GET/PACE bubble understand that ME/CFS is a physiological disease and that faulty “cognitive processes” have nothing to do with perpetuating or contributing to it.

The Dutch study found that those assigned to FITNET reported less fatigue, greater physical function, and greater school attendance than those in the comparison group, who received standard treatment–referred to as “usual care.” And using a composite definition of “recovery,” the study reported that 63% of those in the FITNET group–just shy of two-thirds–“recovered” at six months, compared to just eight percent in the comparison group. But this apparent success masks a much more complicated reality and cannot be taken at face value, for multiple reasons.

First, the subsequent 2013 paper from the Dutch team found no differences in “recovery” between participants in the two groups at long-term follow-up (on average, 2.7 years after starting). Those in the comparison group improved after the trial and had caught up to the intervention group, so the online CBT conferred no extended advantages or benefits. The researchers argued that the therapy was nonetheless useful because patients achieved gains more quickly. But they failed to consider another reasonable explanation for their results.

Those in usual care were attending in-person sessions at clinics or doctors’ offices. Depending on how often they went, how far they had to travel and how sick they were, the transportation demands could easily have triggered relapses and harmed their health. In contrast, those in the FITNET group could be treated at home. Perhaps they improved not from the treatment itself but from an unintended side effect–the sedentary nature of the intervention allowed them more time to rest. The investigators did not control for this aspect of the online CBT.

Second, the “recovery” figure in the Dutch FITNET study was a post-hoc calculation, as the authors acknowledged. The protocol for the trial included the outcomes to be measured, of course, but the authors did not identify before the trial what thresholds participants would need to meet to be considered “recovered.” The entire definition was constructed only after they saw the results—and the thresholds they selected were extremely lenient. Even two of the PACE authors, in a Lancet commentary praising the Dutch study, referred to the “recovery” criteria as “liberal” and “not stringent.” (In fact, only 36% “recovered” under a more modest definition of “recovery,” but the FITNET authors tucked this finding into an appendix and Dr. Crawley’s FITNET-NHS protocol didn’t mention it.)

Now, the fact that “recovery” was a post-hoc measure doesn’t mean it isn’t valid. But anyone citing this “recovery” rate should do so with caveats and some measure of caution. Dr. Crawley has exhibited no such reticence—in a recent radio interview, she declared flatly that the Dutch participants had made a “full recovery.” (In the same interview, she called PACE “a great, great study.” Then she completely misrepresented the results of the recent reanalyses of the PACE trial data. So, you know, take her words for what they’re worth.)

Given the hyperbole about “recovery,” the public is understandably likely to assume that Dr. Crawley’s new “landmark” study will result in similar success. A corollary of that assumption is that anyone who opposes the study’s approach, like so many in the patient and advocacy communities, could be accused of acting in ways that harm children by depriving them of needed treatment. This would be an unfair charge, since the online CBT being offered is based on the questionable premise that the children harbor untrue cognitions about their illness.

Third, the standard treatments received by the usual care group were described like this: “individual/group based rehabilitation programs, psychological support including CBT face-to-face, graded exercise therapy by a physiotherapist, etc.” In other words, pretty much the kinds of “evidence-based” strategies these Dutch experts and their U.K. colleagues had promoted for years as being effective for chronic fatigue syndrome. In the end, two-thirds of those in usual care received in-person CBT, and half received graded exercise therapy. (Many participants in this arm received more than one form of usual care.)

And yet less than one in ten of the usual care participants were found to have “recovered” at six months, according to the 2012 study. So what does that say about the effectiveness of these kinds of rehabilitative approaches in the first place? In light of the superlative findings for online CBT, why haven’t all chronic fatigue syndrome patients in the Netherlands now been removed from in-person treatments and offered this more convenient option? (Dr. Crawley’s FITNET-NHS proposal tried to explain away this embarrassing finding of the Dutch study by suggesting that those providing usual care were not trained to work with this kind of population.)

Finally, the Dutch study did not report any objective measures of physical performance. Although the study included assessments using an actometer—an ankle bracelet that monitors distance moved—the Lancet paper did not mention those results. In previous studies of cognitive and behavioral treatments for ME/CFS, reported improvements on subjective measures for fatigue or physical function were not accompanied by increases in physical movement, as measured by actometer. And in PACE, of course, the investigators dismissed their own objective measures as irrelevant or non-objective—after these outcomes failed to provide the desired results.

In response to correspondence calling for publication of the actometer data, the Dutch investigators refused, noting that “the goal of our treatment was reduction of fatigue and increase in school attendance, not increase in physical activity per se.” This is an inadequate explanation for the decision to withhold data that would shed light on whether participants actually improved in their physical performance as well as in their subjective impressions of their condition. If the actometer data demonstrated remarkable increases in activity levels in the online CBT group, is there any doubt they would have reported it?

In short, the Dutch FITNET study leaves a lot of questions unanswered. So does its U.K. version, the proposed FITNET-NHS. And Dr. Crawley’s recent media blitz—which included a “can’t-we-all-get-along” essay in The New Scientist—did little to quell any of the reasonable qualms observers might have about this latest effort to bolster the sagging fortunes of the CBT/GET/PACE paradigm.

“Patients are desperate for this trial, yet some people are still trying to stop us,” wrote Dr. Crawley in The New Scientist. “The fighting needs to end.”

However, those mysterious and sinister-sounding “some people” cited by Dr. Crawley have very thoughtful and legitimate reasons for questioning the quality of her research. The fighting, as she calls it, is likely to end when Dr. Crawley and her colleagues stop conflating chronic fatigue and chronic fatigue syndrome through the use of loose diagnostic criteria. And when they acknowledge what scientists in the U.S. and around the world now understand: The claim that cognitive and behavioral approaches are effective treatments that lead to “recovery” is based on deeply flawed research.

Read the full article

David Tuller is academic coordinator of the concurrent masters degree program in public health and journalism at the University of California, Berkeley.

Posted in News | Tagged , , , , , , , | Comments Off on Tuller says FITNET fraught with misrepresentations & methodological problems

Can mould cause CFS?

Article abstract:

When we talk with Chronic Fatigue Syndrome patients, we learn that before they became ill, some were exposed to water-damaged buildings (WDB) or other mold sources. This raises two questions:

  1. Are people with CFS more likely to have been exposed to WDB or mold than are healthy persons?
  2. If we reduce a CFS patient’s mold burden, would this improve their symptoms?

We can’t answer either question definitively yet. But, both questions are highly relevant – especially the first. One reason is the commercial availability of a new test that measures the amount of mold toxin (mycotoxin) in a person’s urine.

Dr Joseph Brewer’s study concluded that  chronic fatigue syndrome patients are much more likely than healthy people to have mold toxin in their urine. This suggests that mold exposure might be an important causal contributor to CFS.

An examination of that study raises questions about the validity of the comparison between CFS patients and healthy controls. Questions should also be asked of the conclusion that treating for mold helps CFS patients feel better as there was no placebo arm to the study.

For now, all we can say is that Brewer’s results are encouraging but not conclusive. And the mainstream literature is discouraging.

My Bottom Line: Dr. Brewer’s work is strong enough to justify that the CFS-advocacy community invest time and money to do a rigorous controlled study testing whether Dr. Brewer’s potentially critical findings can be reproduced.

BUT be aware that these treatments might or might not in fact be useful and evaluation for mold can be expensive.

Can Mold Cause Chronic Fatigue Syndrome? Is Mold a “Breakthrough” or Just a False Lead? by Richard Podell, MD, MPH, in ProHealth.com, 7 November 2016

podell
Richard Podell, M.D., MPH, is a graduate of Harvard Medical School and the Harvard School of Public Health. He has been treating patients with ME-CFS and Fibromyalgia for more than 20 years.

A clinical professor at New Jersey’s Robert Wood Johnson Medical School, Dr. Podell see patients at his Summit, NJ and Somerset, NJ offices. His website is DrPodell.org

Posted in News | Tagged , , , | Comments Off on Can mould cause CFS?

CFS and chronic widespread pain in adolescence

Research highlights:

  • 14.6% of adolescents with CFS also experienced chronic widespread pain
  • Females twice as likely to have CFS or CWP
  • Exclusive CFS (vs non-CFS) was associated with higher levels of reported pain and greater effect of pain
  • This association attenuated after adjustment for covariates (e.g. depression, anxiety, obesity)
  • Higher levels of depressive & anxiety symptoms are associated with higher odds of comorbid CFS & CWP

Research abstract:

Whilst many studies have investigated the overlap between pain phenotypes and chronic fatigue syndrome (CFS) in adults, little is known about the relationship between these conditions in adolescents.

The study’s aim was therefore to identify whether a relationship exists between chronic widespread pain (CWP) and CFS in adolescents and investigate whether the two share common associations with a set of covariates.

A questionnaire was administered to offspring of the Avon Longitudinal Study of Parents and Children at age 17, asking about site, duration, and pain intensity, from which participants with CWP were identified. At the same research clinic, a computer-based Revised Clinical Interview Schedule (CIS-R) was filled out, from which a
classification of CFS was obtained.

The relationship between selected covariates and CFS and CWP was investigated using a variety of logistic, ordinal logistic and multinomial regressions. We identified 3214 adolescents with complete data for all outcomes and covariates. There were 82 (2.6%) individuals classified as CFS and 145 (4.5%) as CWP. A classification of CFS resulted in an increased likelihood of having CWP (OR: 3.87; 95% CI: 2.05-7.31). Females were approximately twice as likely to have CFS or CWP, with multinomial regression revealing a greater sex-effect for CWP compared to CFS. Those with exclusive CFS were more likely to report higher levels of pain and greater effect of
pain compared to those without CFS, though associations attenuated to the null after adjustment for covariates, which did not occur in those with exclusive CWP.

Multinomial regression revealed that relative to having neither CFS nor CWP, a one-unit increase in the depression and anxiety scales increased the risk of having exclusive CFS and, to a greater extent, the risk of having co-morbid CFS and CWP, but not exclusive CWP, which was only related to anxiety.

Perspective:
In this cohort, 14.6% of adolescents with CFS have co-morbid CWP. The likely greater proportion of more mild cases observed in this epidemiological study means that prevalence of overlap may be underestimated compared to those attending specialist services. Clinicians should be aware of the overlap between the two conditions and carefully consider treatment options offered.

Chronic Fatigue Syndrome and chronic widespread pain in adolescence: Population birth cohort study, by Tom Norris, Kevin Deere, Jon H. Tobias, Esther Crawley in The Journal of Pain [Preprint Available online 12 November 2016]

Posted in News | Tagged , , , , , , , , , , , | Comments Off on CFS and chronic widespread pain in adolescence

The “Starvation” Disease? metabolomics meets CFS down under

Health rising blog post: The “Starvation” Disease? Metabolomics Meets Chronic Fatigue Syndrome Down Under, by Cort Johnson, 10 November 2016

“The pathological nature of the fatigue experienced by ME/CFS sufferers is its inexplicable persistence, severity and its inability to be sufficiently relieved by rest.” Armstrong et. al.

The Naviaux metabolomics study with its findings suggesting that a hypometabolic state is present in chronic fatigue syndrome was thrilling, but it wasn’t the first or even nearly the first ME/CFS metabolomics study. The Aussies (McGregor, Gooley, Butt, and more recently Armstrong) have been plugging away at metabolism and metabolic work for years, and their 2015 study – ignored by most – was as exciting as the Naviaux paper. Ron Davis glommed onto it early and  praised it. Looked at in light of Bob Naviaux’s work, the paper, with its similar core findings and somewhat different interpretations, is exciting indeed.

The Core Problem in Chronic Fatigue Syndrome Identified? Naviaux’s Metabolomics Study Breaks Fresh Ground

metabolomics-armstrong-smci-webinarFrom the Amstrong SMCI webinar

Christopher Armstrong, the lead author, is an example of the kind of young researcher this field needs so much. An Australian researcher working with Neil McGregor – a metabolomics pioneer in the ME/CFS field  – Armstrong represents hope for the future.

Armstrong was not at IACFS/ME conference but Dr. McGregor was. McGregor’s mostly been working in the shadows for years but he’s out of the shadows now and appears to be in considerable demand. He was not being totally ignored before; a year or so ago the Australian group’s work caught the eye of an ME/CFS researcher – Dr. Fluge – who doesn’t miss much.  Dr. Fluge’s subsequent metabolomics work was one of the highlights of the IACFS/ME Conference.

When I asked Armstrong how he got involved in chronic fatigue syndrome (ME/CFS), he noted that Dr. McGregor and Dr. Henry Butt have studied ME/CFS since the early 1990s. After Butt and Gooley published a paper on gut microbes in ME/CFS. Armstrong’s Ph.D. study examined D-lactate in blood, fecal and urine samples. He then got funded for the larger study that was published in 2015.

Continue reading this article for more about Dr Armstrong’s work

Solve ME/CFS webinar with Christopher Armstrong, 20 October 2016

Posted in News | Tagged , , , , , | Comments Off on The “Starvation” Disease? metabolomics meets CFS down under

ME Association’s Metabolomics study appeals for funds

ME Association: Make ME Better! appeal

Our Make ME Better campaign aims to raise £50,000 to fund scientific research which we hope could lead to a breakthrough in diagnosis and treatment of ME/CFS.

Led by Dr Karl Morten, scientists from the University of Oxford and Newcastle University wish to spend 12 months analysing nearly 300 blood samples, looking at metabolomics – chemical clues that are left behind after changes in cells. Put simply, they’re on the hunt for a smoking gun.

The British research will pick up the gauntlet of the groundbreaking Naviaux study released by the University of California earlier this year, which suggested that ME/CFS could be the body going into a state of semi-hibernation.

Dr Morten will be working alongside Dr James McCullagh, Associate Professor in Mass Spectrometry at the University of Oxford, and Professor Julia Newton, Dean for Clinical Medicine at Newcastle University.

Many of the blood samples will come from the ME/CFS Biobank – the first significant time they have been used by external researchers – and will be compared to those from a control group.

IT’S A BIG TARGET BUT PLEASE HELP US REACH IT!

You can support MAKE ME BETTER

For the first time ever, you can involve all your friends and family in fundraising for this appeal – a Santa dash, Christmas party, or community Christmas card……

Once you’ve decided what you want to do, simply click on the ‘Start fundraising’ tab of the campaign page to get started.

Please support our campaign to MAKE ME BETTER in whatever way you can.

Helen Hyland
Fundraising Manager
ME Association

Posted in News | Tagged , , , , | Comments Off on ME Association’s Metabolomics study appeals for funds

B cell functional changes & Ca2+dysregulation in ME/CFS

Research abstract:

Single nucleotide polymorphisms and genotypes of transient receptor potential ion channel and acetylcholine receptor genes from isolated B lymphocytes in myalgic encephalomyelitis/chronic fatigue syndrome patients, by Marshall-Gradisnik S, Johnston S , Chacko A , Nguyen T , Smith P , Staines D 3 in J Int Med Res. 2016 Nov 10. pii [Epub ahead of print]

OBJECTIVE:
The pathomechanism of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is unknown; however, a small subgroup of patients has shown muscarinic antibody positivity and reduced symptom presentation following anti-CD20 intervention. Given the important roles of calcium (Ca2+) and acetylcholine (ACh) signalling in B cell activation and potential antibody development, we aimed to identify relevant single nucleotide polymorphisms (SNPs) and genotypes in isolated B cells from CFS/ME patients.

METHODS:
A total of 11 CFS/ME patients (aged 31.82 ± 5.50 years) and 11 non-fatigued controls (aged 33.91 ± 5.06 years) were included. Flow cytometric protocols were used to determine B cell purity, followed by SNP and genotype analysis for 21 mammalian TRP ion channel genes and nine mammalian ACh receptor genes. SNP association and genotyping analysis were performed using ANOVA and PLINK analysis software.

RESULTS:
Seventy-eight SNPs were identified in nicotinic and muscarinic acetylcholine receptor genes in the CFS/ME group, of which 35 were in mAChM3. The remaining SNPs were identified in nAChR delta (n = 12), nAChR alpha 9 (n = 5), TRPV2 (n = 7), TRPM3 (n = 4), TRPM4 (n = 1) mAChRM3 2 (n = 2), and mAChRM5 (n = 3) genes. Nine genotypes were identified from SNPs in TRPM3 (n = 1), TRPC6 (n = 1), mAChRM3 (n = 2), nAChR alpha 4 (n = 1), and nAChR beta 1 (n = 4) genes, and were located in introns and 3′ untranslated regions. Odds ratios for these specific genotypes ranged between 7.11 and 26.67 for CFS/ME compared with the non-fatigued control group.

CONCLUSION:
This preliminary investigation identified a number of SNPs and genotypes in genes encoding TRP ion channels and AChRs from B cells in patients with CFS/ME. These may be involved in B cell functional changes, and suggest a role for Ca2+dysregulation in AChR and TRP ion channel signalling in the pathomechanism of CFS/ME.

 

Posted in News | Tagged , , , , , , , , , | Comments Off on B cell functional changes & Ca2+dysregulation in ME/CFS

A polysaccharide from Schisandra chinensis fruit might relieve fatigue in CFS?

Research abstract:

Schisandra chinensis fruits are a famous traditional Chinese medicine to treat all kinds of fatigue. This study aimed to investigate the therapeutic effect and metabolic mechanism of a polysaccharide (SCP) from Schisandra chinensis fruits on chronic fatigue syndrome(CFS).

SCP was isolated and the physicochemical properties were analyzed. A CFS model of rats was established and the urinary metabonomic studies were performed using gas chromatography time-of-flight mass spectrometry (GC-TOF-MS) in combination with multivariate statistical analysis. The results showed that SCP is a protein-bound polysaccharide. The amino acid composition of SCP consisted of 12 amino acids.

The growth and the behaviors of the rats in the CFS model group were worse than those in the control group and improved after SCP treatment. Analysis of the GC-TOF-MS revealed that twelve metabolites were significantly changed, and six metabolites were oppositely and significantly changed after the SCP treatment. The TCA cycle metabolic pathways and the alanine, aspartate and glutamate metabolism were identified as significant metabolic pathways involved with SCP. The therapeutic mechanism of SCP against CFS was partially due to the restoration of these disturbed pathways.

Metabolic mechanism of a polysaccharide from Schisandra chinensis to relieve chronic fatigue syndrome, by A Chi, Y Zhang, Y Kang, Z  in Int J Biol Macromol. 2016 Aug 18;93(Pt A):322-332 [Epub ahead of print]

Posted in News | Tagged , , | Comments Off on A polysaccharide from Schisandra chinensis fruit might relieve fatigue in CFS?

Countess of Mar complains about BBC portrayal of FITNET trial

The Countess of Mar has written to the Director General of the BBC with a formal complaint about its portrayal of the FITNET trial from 1 Nov 2016 onwards.

3rd November 2016

Dear Lord Hall
Formal Complaint to the BBC re: the purveying of mis-information on 1st November 2016

This is brought to your personal attention because it is such a serious matter.

The BBC is required to be accurate and impartial, but James Gallagher (the BBC News
website Health and Science reporter who was responsible for the item that made the BBC
headlines from 5.30am on 1st November 2016) was neither accurate nor impartial.
On BBC News 24 the breaking news ticker headline repeatedly announced across the screen:

“A successful treatment for children with CFS is being trialled by the NHS.”

The BBC’s Charter says that its primary function is to inform, educate and entertain, but the BBC breached its own Charter by its 24-hour non-stop promotion of a study of myalgic
encephalomyelitis/chronic fatigue syndrome in children and adolescents (the £1 million
FITNET trial, which stands for Fatigue In Teenagers on the interNET) and which claims
success for a behavioural modification intervention when there is no objective evidence of
any such success in either children, adolescents or adults.

Moreover, the study had not even started to recruit participants: this was not made clear and it was heralded as “Landmark chronic fatigue trial could cure two-thirds” but that was later changed to the nonsensical “Landmark chronic fatigue trial could treat two-thirds“. Chronic fatigue is not the same as ME/CFS.

The item was described thus:

“the BBC and their scientifically illiterate journalists imaginatively and dishonestly spun this as a 2/3 cure rate”.

The letter goes on to look at specific aspects of the complaint and then ends:

I ask that you ensure that the BBC issues a prominent retraction of its endorsement of and
support for the FITNET study and, to counter-balance its support for behavioural
interventions for a proven and classified neuroimmune disorder, the BBC offers a
commensurate right of reply to those with an understanding of the biomedical nature of the disease.

Read full letter

Posted in News | Tagged , | 1 Comment

Targeting serotonin and insulin-like growth factor in CFS

Thesis outline:

Given the controversies and uncertainties surrounding these potentially important mediators in CFS, we decided to investigate the role of tryptophan, 5-HT and IGF-1 in CFS in this thesis. Our studies aim to obtain a deeper insight into the pathophysiology of CFS by investigating the efficacy of three biological interventions for CFS.

The effect of Granisetron, a 5-HT3 receptor antagonist, in CFS – In chapter 2 we asked the question whether treatment with a 5-HT3 receptor antagonist is effective in CFS. Studies and clinical observations suggested a role for 5-HT3 receptor antagonism in the treatment of chronic fatigue associated with chronic liver disease and fibromyalgia. The effect of 5-HT3 receptor antagonists in CFS patients had not been investigated in CFS patients before, hence a pilot study was carried out to investigate the effect of Granisetron.

The effect of Ondansetron, a 5-HT3 receptor antagonist, in CFS– In chapter 3 we addressed the same question based on positive findings found in the pilot study described in chapter 2. A randomised double-blind controlled trial was performed. Because granisetron was no longer available at that time, due to a merge of pharmaceutical manufacturer SmithKline Beecham with Glaxo Wellcome, the 5-HT3 antagonist Ondansetron (Zofran) was used to further investigate the effect of 5-HT3 receptor antagonism in CFS.

The effect of Acute Tryptophan Depletion in CFS – Besides intervention with selective serotonin antagonists, we also investigated the effect of Acute Tryptophan Depletion (ATD), a well-known intervention in major depressive disorder The results of a placebo-controlled cross-over ATD study are presented in chapter 4.

Based on the hypothesis that CFS represents a hyperserotonergic state, we used ATD to decrease central serotonin availability, and assessed the effects on fatigue severity, concentration and mood.

The effect of Acclydine in CFS – In chapter 5 we investigated whether CFS patients have lower IGF-1 levels than age, weight and gender matched neighbourhood controls.

Based on the idea that the growth hormone metabolism is disrupted in CFS, De Meirleir in 2001 reported that treatment with Acclydine, a plant-sourced alkaloid, is effective in modifying growth hormone/

IGF-1 status in adult CFS patients and reverts complaints. In 2002, the CFS patient organisation reported in their ‘MEdium Journal’ that the manufacturer of Acclydine had found that 75-80% of CFS patients have a growth hormone deficiency.

Double-blind randomised controlled trials were needed. Acclydine was an expensive treatment and is available on the internet without a prescription. It had been mentioned on the news that Acclydine was recommended for cancer patients with chronic fatigue, and that there were conflicts in Acclydine research. Acclydine was administered to vulnerable patients, but the scientific evidence for efficacy was lacking. The effect of Acclydine, officially a food supplement, was thus evaluated in a randomised controlled clinical trial. We evaluated whether Acclydine is effective in CFS by increasing biologically active IGF-1 levels. Results of a randomised controlled trial are presented in this thesis.

[Comment from M Fluks: Chapter 5 debunks Acclydine therapy. In The Netherlands and Belgium problems arose after Acclydine was sold to PWCs, PWFMs, and Cancer patients (Cancer patients even died due to lack of treatment). Afterwards, things would never be the same: Acclydine therapy marked the beginning of the end of CFS in The Netherlands  and Belgium.]

Discussion and future prospects – In chapter 6 I will discuss the main results and implications of the investigations performed, and present recommendations and prospects for future studies.

Chronic Fatigue Syndrome: Targeting Serotonin and Insulin-like Growth Factor, by Gerard Kong Han The. Thesis from Radboud University Nijmegen Medical Centre, 1 Nov 2016

http://repository.ubn.ru.nl/handle/2066/160772

Posted in News | Tagged , , , , , , | Comments Off on Targeting serotonin and insulin-like growth factor in CFS